» Articles » PMID: 38502430

Convection-Enhanced Drug Delivery: Experimental and Analytical Studies of Infusion Behavior in an In Vitro Brain Surrogate

Overview
Journal Ann Biomed Eng
Date 2024 Mar 19
PMID 38502430
Authors
Affiliations
Soon will be listed here.
Abstract

Convection-enhanced drug delivery (CED) directly infuses drugs with a large molecular weight toward target cells as a therapeutic strategy for neurodegenerative diseases and brain cancers. Despite the success of many previous in vitro experiments on CED, challenges still remain. In particular, a theoretical predictive model is needed to form a basis for treatment planning, and developing such a model requires well-controlled injection tests that can rigorously capture the convective (advective) and diffusive transport of an infusate. For this purpose, we investigated the advection-diffusion transport of an infusate (bromophenol blue solution) in the brain surrogate (0.2% w/w agarose gel) at different injection rates, ranging from 0.25 to 4 μL/min, by closely monitoring changes in the color intensity, propagation distance, and injection pressures. One dimensional closed-form solution was examined with two variable sets, such as the mathematically calculated coefficient of molecular diffusion and average velocity, and the hydraulic dispersion coefficient and seepage velocity by the least squared method. As a result, the seepage velocity was greater than the average velocity to some extent, particularly for the later infusion times. The poroelastic deformation in the brain surrogate might lead to changes in porosity, and consequently, slight increases in the actual flow velocity as infusion continues. The limitation of efficiency of the single catheter was analyzed by dimensionless analysis. Lastly, this study suggests a simple but robust approach that can properly capture the convective (advective) and diffusive transport of an infusate in an in vitro brain surrogate via well-controlled injection tests.

References
1.
Silva G . Nanotechnology approaches to crossing the blood-brain barrier and drug delivery to the CNS. BMC Neurosci. 2008; 9 Suppl 3:S4. PMC: 2604882. DOI: 10.1186/1471-2202-9-S3-S4. View

2.
Song D, Lonser R . Convection-enhanced delivery for the treatment of pediatric neurologic disorders. J Child Neurol. 2008; 23(10):1231-7. PMC: 3674562. DOI: 10.1177/0883073808321064. View

3.
Fleming A, Saltzman W . Pharmacokinetics of the carmustine implant. Clin Pharmacokinet. 2002; 41(6):403-19. DOI: 10.2165/00003088-200241060-00002. View

4.
Sindhwani N, Ivanchenko O, Lueshen E, Prem K, Linninger A . Methods for determining agent concentration profiles in agarose gel during convection-enhanced delivery. IEEE Trans Biomed Eng. 2011; 58(3):626-32. DOI: 10.1109/TBME.2010.2089455. View

5.
Bobo R, Laske D, Akbasak A, Morrison P, Dedrick R, Oldfield E . Convection-enhanced delivery of macromolecules in the brain. Proc Natl Acad Sci U S A. 1994; 91(6):2076-80. PMC: 43312. DOI: 10.1073/pnas.91.6.2076. View